Risk assessment report on gadolinium-containing contrast agents in end-stage renal disease patients [J]. Lancet, Abercrombie vente, 2000, 356: 1000-01.
[5] LeBoit PE. What nephrogenic fibrosing dermopathy might be [J]. Arch Dermatol, 2003, 139: 928-30.
[6] Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement [J]. Arch Dermatol, 2003, 139: 903-06.
[7] Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review [J]. Am J Kidney Dis, 2005, north face online shop, 46: 754-59.
[8] Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy [J]. Am J Dermatopathol, 2001, 23: 383-93.
[9] McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis [J]. Int J Dermatol, 2002, 41: 364-67.
[10] Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years [J]. Curr Opin Rheumatol, 2003, 15: 785-90.
[11] Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy [J]. Ann Intern Med, 2006, 145: 234-35.
[12] Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? [J]. Arch Dermatol, 2004, ugg outlet, 140: 1401.
[13] Mackay, Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease) [J]. J Am Acad Dermatol, 2003, 48: 55-60.
[14] Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, still much unclear [J]. Am J Dermatopathol, 2003, 25: 358.
[15] Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis [J]. Curr Rheumatol Rep, nike free run, 2006, 8: 145-50.
(The Quoted http://www.mhra.gov.uk)
(This article has more articles related to topics: new balance 993 fjy dvbt oems nike free run gej mqpa azdj canada goose tilbud ate qiet alxg)